Related Experiment Video
Updated: Jun 10, 2026
Dual Effects of Melanoma Cell-derived Factors on Bone Marrow Adipocytes Differentiation
Published on: August 23, 2018
Glucocorticoid-induced differentiation of primary cultured bone marrow mesenchymal cells into adipocytes is
Le Lin1, Shun-Dong Dai, Guang-Yu Fan
1Departments of Orthopedics, First Affiliated Hospital China Medical University, Shenyang 110001, China.
Abstract:
Long-term clinical use of glucocorticoids often causes the serious side effect of non-traumatic avascular osteonecrosis. The aim of this study was to examine the effects and mechanisms of a glucocorticoid, dexamethasone (Dex), on differentiation of primary cultured rat bone marrow mesenchymal cells (BMCs). We also tried to block the inhibitory effects of Dex on osteoblast differentiation. Adipocyte markers (peroxisome proliferator-activated receptorgamma-2 and aP2) were increased in response to Dex treatment in a dose- and time-dependent manner, while osteoblastic markers [Runx2, COL 1, osterix, alkaline phosphatase (ALP) and OC] were down-regulated, consistent with ALP and osteocalcin promoter activity. To validate the effects of Runx2 on the expression of osteogenesis and adipocyte genes, pCMV/Flag-Runx2 was transfected into BMCs, and relevant markers were detected after 10(-7) M Dex treatment for 48 h. The results indicated that Dex treatment induced adipogenic differentiation and suppressed proliferation. No significant difference was detected in expressions of these genes between Runx2-transfected cells and Dex-treated BMCs. These data suggest that Dex primarily induced adipocyte differentiation of BMCs. Exogenous Runx2 can antagonize the effect of Dex on osteoblast differentiation.
Insights
Glucocorticoids like dexamethasone promote fat cell (adipocyte) differentiation and inhibit bone cell (osteoblast) formation in bone marrow cells. Adding Runx2 can counteract these effects, potentially preventing steroid-induced bone loss.
Area of Science:
- Cell Biology
- Biochemistry
- Endocrinology
Background:
- Long-term glucocorticoid use can lead to avascular osteonecrosis.
- Understanding glucocorticoid effects on bone marrow cells is crucial for preventing side effects.
Purpose of the Study:
- To investigate how dexamethasone (Dex) affects bone marrow mesenchymal cell (BMCs) differentiation.
- To explore mechanisms underlying Dex-induced osteonecrosis and potential interventions.
Main Methods:
- Primary rat bone marrow mesenchymal cells (BMCs) were cultured and treated with dexamethasone (Dex).
- Gene expression of adipocyte and osteoblast markers was analyzed.
- Runx2 was overexpressed in BMCs to assess its effect on Dex-induced differentiation.
Main Results:
- Dex treatment increased adipocyte markers (PPARγ2, aP2) and decreased osteoblast markers (Runx2, COL1, Osterix, ALP, OC) in a dose- and time-dependent manner.
- Dex suppressed BMC proliferation and promoted adipogenic differentiation.
- Overexpression of Runx2 partially antagonized the inhibitory effects of Dex on osteoblast differentiation.
Conclusions:
- Dexamethasone primarily induces adipogenic differentiation of bone marrow mesenchymal cells.
- Exogenous Runx2 can counteract the negative effects of Dex on osteoblast differentiation, suggesting a potential therapeutic strategy.
